All In MedTech

Device Trial Radar · NCT03164551

TICON-Day 3, Time Lapse Versus Conventional Method in Day 3 Embryo Culture and Assessment

A Phase IV, Single-blinded, Prospective, Randomized, Controlled, Multi-center Study to Compare the Clinical Outcomes of Genea Embryo Review Instrument Plus (GERI+) Time Lapse System With a Conventional Embryo Culture and Assessment System

Last checked: Nov 19, 2026Latest source record: Dec 2, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 408 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

408

Actual

Start

Apr 16, 2018

Primary completion

Nov 20, 2019

Study completion Nov 20, 2019

Sponsor

Lead sponsor
Merck KGaA, Darmstadt, GermanyNot on our public-company list
Sponsor type
Industry
First posted
May 23, 2017

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main purpose of the study was to evaluate the overall clinical value of GERI+ as an integrated embryo culture and assessment system, providing an undisturbed culture environment, continuous monitoring of embryo development and automated scoring using a predictive algorithm.

Conditions

  • Infertility

Interventions

  • GERI+ incubatorDevice

    The embryo culture of consented participants were carried out in GERI+ incubator for both bright-field and dark-field time lapse monitoring until Day 3 of embryo culture. On Day 3, all embryos were reviewed firstly by GERI Assess software, using bright-field imaging. Finally the embryo(s) with the highest EEVA grade are transferred were followed up until the achievement of implantation and confirmation of pregnancy.

  • Conventional incubatorDevice

    The embryo culture of consented participants were carried out in conventional incubator for culture until Day 3 of embryo culture. On Day 3 of embryo culture, all embryos are assessed using a bench-top microscope. The embryo(s) with optimal cell stage and grade were transferred and were followed up until the achievement of implantation and confirmation of pregnancy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Pregnancy Rate With Positive Fetal Heart Beat (FHB)Time frame: Gestation Weeks 6 to 8

Locations

17 sites in 7 countries. Site status is shown where the registry gives one.

  • Cambrian Wellness Centre

    Calgary, Canada

  • Regional Fertility Program

    Calgary, Canada

  • Skive Fertility clinic

    Skive, Denmark

14 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.